Acute Spinal Cord Injury
4
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
DS
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
PharmazzNormal Saline along with standard treatment
United TherapeuticsAC105
Daiichi SankyoSUN13837 injection
NovartisATI355
Clinical Trials (4)
Total enrollment: 172 patients across 4 trials
PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury
Start: Jan 2019Est. completion: Jul 202640 patients
Phase 2Recruiting
AC105 in Patients With Acute Traumatic Spinal Cord Injury
Start: Jul 2013Est. completion: May 201515 patients
Phase 2Terminated
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)
Start: Aug 2012Est. completion: Sep 201465 patients
Phase 2Completed
Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI
Start: May 2006Est. completion: Sep 201152 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 172 patients
4 companies competing in this space